S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Ekso Bionics Stock Forecast, Price & News

-0.08 (-2.49%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
290,852 shs
Average Volume
97,436 shs
Market Capitalization
$39.63 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive EKSO News and Ratings via Email

Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter.

Ekso Bionics logo

About Ekso Bionics

Ekso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following segments: EksoHealth and EksoWorks. The EksoHealth segment consists of the engineering, manufacture and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in Richmond, CA.


Comparing Berkshire Grey (NASDAQ:BGRY) & Ekso Bionics (NASDAQ:EKSO)
November 19, 2021 |  americanbankingnews.com
Analyzing Ekso Bionics (NASDAQ:EKSO) & Berkshire Grey (NASDAQ:BGRY)
November 14, 2021 |  americanbankingnews.com
Ekso Bionics Reports Third Quarter 2021 Results
November 2, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

General industrial machinery,
Current Symbol
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$8.88 million
Book Value
$3.08 per share


Net Income
$-15.82 million
Net Margins
Pretax Margin




Free Float
Market Cap
$39.63 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.76 out of 5 stars

Medical Sector

881st out of 1,388 stocks

General Industrial Machinery, Industry

6th out of 11 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Ekso Bionics (NASDAQ:EKSO) Frequently Asked Questions

Is Ekso Bionics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ekso Bionics stock.
View analyst ratings for Ekso Bionics
or view top-rated stocks.

How has Ekso Bionics' stock been impacted by Coronavirus?

Ekso Bionics' stock was trading at $0.2616 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EKSO shares have increased by 1,096.5% and is now trading at $3.13.
View which stocks have been most impacted by COVID-19

Are investors shorting Ekso Bionics?

Ekso Bionics saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 202,000 shares, an increase of 42.8% from the October 14th total of 141,500 shares. Based on an average daily trading volume, of 121,300 shares, the days-to-cover ratio is currently 1.7 days. Currently, 1.6% of the shares of the company are sold short.
View Ekso Bionics' Short Interest

When is Ekso Bionics' next earnings date?

Ekso Bionics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Ekso Bionics

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) posted its quarterly earnings data on Monday, November, 1st. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.10. Ekso Bionics had a negative net margin of 115.42% and a negative trailing twelve-month return on equity of 41.27%. During the same period in the prior year, the firm posted ($0.52) EPS.
View Ekso Bionics' earnings history

When did Ekso Bionics' stock split? How did Ekso Bionics' stock split work?

Ekso Bionics shares reverse split before market open on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of Ekso Bionics stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for EKSO?

2 Wall Street analysts have issued 1-year target prices for Ekso Bionics' shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate Ekso Bionics' share price to reach $11.00 in the next year. This suggests a possible upside of 251.4% from the stock's current price.
View analysts' price targets for Ekso Bionics
or view top-rated stocks among Wall Street analysts.

Who are Ekso Bionics' key executives?

Ekso Bionics' management team includes the following people:
  • Jack Peurach, President, Chief Executive Officer & Director
  • John F. Glenn, Chief Financial Officer
  • William Shaw, Chief Commercial Officer
  • Stephan Aderhold, Vice President-EMEA Sales & Marketing
  • Jason Jones, Vice President-Product Development

What other stocks do shareholders of Ekso Bionics own?

What is Ekso Bionics' stock symbol?

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

Who are Ekso Bionics' major shareholders?

Ekso Bionics' stock is owned by a number of retail and institutional investors. Top institutional investors include Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends for Ekso Bionics

Which major investors are selling Ekso Bionics stock?

EKSO stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC.
View insider buying and selling activity for Ekso Bionics
or view top insider-selling stocks.

How do I buy shares of Ekso Bionics?

Shares of EKSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ekso Bionics' stock price today?

One share of EKSO stock can currently be purchased for approximately $3.13.

How much money does Ekso Bionics make?

Ekso Bionics has a market capitalization of $39.63 million and generates $8.88 million in revenue each year. The company earns $-15.82 million in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does Ekso Bionics have?

Ekso Bionics employs 40 workers across the globe.

What is Ekso Bionics' official website?

The official website for Ekso Bionics is www.eksobionics.com.

Where are Ekso Bionics' headquarters?

Ekso Bionics is headquartered at 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804.

How can I contact Ekso Bionics?

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company can be reached via phone at (510) 984-1761, via email at [email protected], or via fax at 510-927-2647.

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.